May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Infliximab, Optic Neuropathy and Giant Cell Arteritis
Author Affiliations & Notes
  • J. G. McHenry
    Ophthalmology, UT Southwestern, Dallas, Texas
  • R. Weinstein
    Ophthalmology, UT Southwestern, Dallas, Texas
  • Footnotes
    Commercial Relationships J.G. McHenry, None; R. Weinstein, None.
  • Footnotes
    Support RPB
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 921. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. G. McHenry, R. Weinstein; Infliximab, Optic Neuropathy and Giant Cell Arteritis. Invest. Ophthalmol. Vis. Sci. 2007;48(13):921.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To show a case of optic neuropathy intolerant of steroids successfully treated with infliximab.

Methods:: The records of a 68 year old patient with temporal pain, jaw claudication and visual loss treated with infliximab were reviewed.

Results:: Visual fields normalized and symptoms immediately improved.

Conclusions:: Infliximab is an indirect T cell inhibitor. It is a mouse-human IgG1 chimeric anti-tumor necrosis (TNFa) factor monoclonal antibody. It inhibits the binding of TNFa with its receptor. TNFa induces interleukin 1 and 6 which in turn lead to T cell migration. As giant cell arteritis is a T cell mediated disease, infliximab may offer a way to arrest visual loss in emergent giant cell arteritis, as its response may occur within hours.

Keywords: neuro-ophthalmology: optic nerve • immunomodulation/immunoregulation • ischemia 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.